Bellevue Group AG Decreases Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Bellevue Group AG trimmed its position in Omnicell, Inc. (NASDAQ:OMCL) by 16.0% in the 3rd quarter, Holdings Channel.com reports. The fund owned 197,714 shares of the company’s stock after selling 37,658 shares during the quarter. Bellevue Group AG’s holdings in Omnicell were worth $8,620,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of OMCL. Assenagon Asset Management S.A. boosted its position in shares of Omnicell by 61.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock worth $16,240,000 after purchasing an additional 228,093 shares in the last quarter. Federated Hermes Inc. boosted its holdings in Omnicell by 1,113.6% in the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock worth $26,830,000 after acquiring an additional 909,480 shares in the last quarter. Royce & Associates LP purchased a new stake in shares of Omnicell during the third quarter worth about $811,000. Liontrust Investment Partners LLP acquired a new position in shares of Omnicell during the second quarter valued at about $4,066,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Omnicell by 750.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 294,037 shares of the company’s stock valued at $12,820,000 after purchasing an additional 259,463 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on OMCL. Wells Fargo & Company boosted their target price on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research report on Monday, October 14th. Craig Hallum upped their target price on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. lifted their price target on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Benchmark reissued a “buy” rating and issued a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Finally, StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a research note on Wednesday. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $52.00.

Omnicell Stock Performance

Shares of OMCL opened at $46.59 on Friday. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.74. The stock’s 50-day moving average price is $44.55 and its 200-day moving average price is $37.99.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.